Therefore, targeting the BAP1-CAMK2D (CAMKII delta) signaling axis is a promising therapeutic approach for most MMe cases and BAP1 tumor predisposition syndrome. This evidence concerns the gene CAMK2D and BAP1-related tumor predisposition syndrome.